BEAM
Beam Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.14B
P/E Ratio
—
EPS
$-0.81
Beta
2.19
52W High
$36.44
52W Low
$15.35
50-Day MA
$27.09
200-Day MA
$24.89
Dividend Yield
—
Profit Margin
-57.20%
Forward P/E
—
PEG Ratio
—
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $139.74M |
| Gross Profit (TTM) | $-269.88M |
| EBITDA | $-361.40M |
| Operating Margin | -15.30% |
| Return on Equity | -8.11% |
| Return on Assets | -18.50% |
| Revenue/Share (TTM) | $1.41 |
| Book Value | $12.48 |
| Price-to-Book | 2.42 |
| Price-to-Sales (TTM) | 22.47 |
| EV/Revenue | 13.64 |
| EV/EBITDA | -7.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 279.50% |
| Shares Outstanding | $102.75M |
| Float | $87.92M |
| % Insiders | 1.36% |
| % Institutions | 103.75% |
Historical Volatility
HV 10-Day
84.24%
HV 20-Day
70.95%
HV 30-Day
69.97%
HV 60-Day
70.79%
HV Rank
38.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($51.20 target)
1
Strong Buy14
Buy2
HoldData last updated: 4/29/2026